Medicus Pharma Ltd. (MDCXW)
NASDAQ (CM) NASDAQ (CM) Primary Summary
MDCXW Chart
Medicus Pharma Ltd. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Anthony Scaramucci SkyBridge Capital II LLC | 60,600 | $42,420 | $27,276.06 | -$15,143.94 | -35.7% |
Medicus Pharma Ltd. (MDCXW) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Medicus Pharma Ltd. ever had a stock split?
Medicus Pharma Ltd. Profile
| Biotechnology Industry | Healthcare Sector | Raza Bokhari CEO | NASDAQ (CM) Exchange | 58471K111 CUSIP |
| US Country | 16 Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
Medicus Pharma Ltd. emerges as a pioneering force in the biotechnological arena, concentrating its efforts on the clinical-stage development of innovative therapeutic solutions. At its core, Medicus Pharma Ltd. is committed to expediting the advancement of novel therapeutic assets, aiming to transform the landscape of treatment methodologies. Its strategic initiative is embodied by its lead subsidiary, SkinJect Inc., which stands at the forefront of developing groundbreaking treatments for debilitating conditions such as basal cell carcinoma. By harnessing the power of advanced biotechnological tools and processes, Medicus Pharma Ltd. is setting new standards in the delivery of healthcare solutions, indicating a robust framework for growth and innovation within the pharmaceutical industry.
Products and Services
- Non-invasive Treatment for Basal Cell Carcinoma
SkinJect Inc., a subsidiary of Medicus Pharma Ltd., is pioneering the development of a novel, non-invasive treatment option for basal cell carcinoma, the most common form of skin cancer. This cutting-edge therapy utilizes a dissolvable microneedle patch to directly target tumor cells. The patch delivers chemotherapeutic agents precisely where needed, minimizing the adverse effects traditionally associated with systemic chemotherapy. This innovative approach not only promises to enhance the efficacy and safety profile of cancer treatment but also ensures a patient-friendly delivery method that could significantly improve the quality of life for individuals battling basal cell carcinoma.
